BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9417379)

  • 1. [Optimal tumor therapy with cytoprotection by ETHYOL (Amifostine). 32nd Annual Session of the American Society of Clinical Oncology in Philadelphia 18-21 May 1996].
    Dtsch Med Wochenschr; 1996 Sep; 121(36 Suppl Fur Die):1-6. PubMed ID: 9417379
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings of the Fourth International Cytoprotection Investigators' Congress. May 2004. Philadelphia, Pennsylvania, USA.
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):1-73. PubMed ID: 15801121
    [No Abstract]   [Full Text] [Related]  

  • 3. Future development of amifostine as a radioprotectant.
    Werner-Wasik M
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifostine in clinical oncology: current use and future applications.
    Koukourakis MI
    Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Amifostine for Cytoprotection during Radiation Therapy: A Review.
    King M; Joseph S; Albert A; Thomas TV; Nittala MR; Woods WC; Vijayakumar S; Packianathan S
    Oncology; 2020; 98(2):61-80. PubMed ID: 31846959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indications for use of amifostine.
    Santolaya-Perrin R; Castillo-Romera I; Requena-Caturla T
    Am J Health Syst Pharm; 1998 Sep; 55(17):1827-8. PubMed ID: 9775347
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized trials of amifostine and radiotherapy: effect on survival?
    Bourhis J; Thephamongkhol K; Pignon JP
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):62-6. PubMed ID: 15726526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of amifostine as a radioprotector.
    Wasserman TH; Brizel DM
    Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
    Capizzi RL; Oster W
    Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoprotection for radiation-associated normal tissue injury.
    Mao J; Fatunase OA; Marks LB
    Cancer Treat Res; 2008; 139():307-27. PubMed ID: 18236722
    [No Abstract]   [Full Text] [Related]  

  • 11. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J; Rosine D
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings of the 3rd International Cytoprotection Investigators' Congress. May 15-18, 2003, Nevis, West Indies.
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):1-108. PubMed ID: 14727234
    [No Abstract]   [Full Text] [Related]  

  • 13. Amifostine and radiation therapy: past, present, and future.
    Tannehill SP; Mehta MP
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):69-77. PubMed ID: 8783671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Amifostine as a supporting treatment during cancer therapy].
    Jantunen E; Puistola U
    Duodecim; 1999; 115(11):1223-7. PubMed ID: 11877841
    [No Abstract]   [Full Text] [Related]  

  • 15. Amifostine.
    Rasey JS
    Cancer Biother Radiopharm; 1999 Oct; 14(5):331-5. PubMed ID: 10850317
    [No Abstract]   [Full Text] [Related]  

  • 16. Established and emerging uses of cytoprotection in head and neck cancer.
    Rosenthal DI
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):129-30. PubMed ID: 16490868
    [No Abstract]   [Full Text] [Related]  

  • 17. Guidelines for the administration of amifostine.
    Schuchter LM
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):40-3. PubMed ID: 8783665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):1-2. PubMed ID: 10348254
    [No Abstract]   [Full Text] [Related]  

  • 19. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
    Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
    J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.